Who's on first for Icahn departee Alex Denner?

After reportedly adding $2 billion to Carl Icahn's (photo) treasure chest, Alex Denner is now off on his own, setting up a new hedge fund that presumably will set out to follow the same biotech blueprint that has worked so well in the past. Report

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.